Holen Sie sich die Stockscreener-App
18.26
1.50%
0.27
Vorhandelsmarkt:
18.64
0.38
+2.08%
Uniqure N V Aktie (QURE) Neueste Nachrichten
uniQure N.V. Securities Fraud Class Action Result of FDA - GlobeNewswire
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $31 to $70 - 富途牛牛
uniQure N.V. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before April 13, 2026 to Discuss Your RightsQURE - Morningstar
uniQure's (QURE) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
QURE ALERT: FDA Reportedly Accuses uniQure of Pushing "Distorted" and "Manipulated" Data For "Failed" AMT-130 Drug Amid Pending Securities Class ActionHagens Berman - PR Newswire
uniQure Shares Surge 26% On US FDA Shakeup Even As Momentum Tumbles: Will New Leadership Greenlight Huntington's Therapy? - Benzinga
uniQure (QURE) Shares Set for Growth Amid Regulatory Changes - GuruFocus
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure - Stocktwits
uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
UniQure N.V. (QURE): RBC Capital Upgrades Rating to Outperform With Significant Upside Potential - 富途牛牛
QURE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - TMX Newsfile
uniQure (QURE) Stock Soars 36% as FDA’s Vinay Prasad Plans April Exit - MEXC
QURE INVESTOR ALERT: uniQure Faces Securities Class Action - GlobeNewswire
QURE DEADLINE: Investors of uniQure N.V. (QURE) are Encouraged to - The National Law Review
Levi & Korsinsky Notifies Shareholders of uniQure N.V.(QURE) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewswire Inc.
QURE Gains Momentum with Chardan Capital's Increased Price Target | QURE Stock News - GuruFocus
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - GlobeNewswire
What the Options Market Tells Us About uniQure - Benzinga
Dragomir News: UniQure’s Price Volatility Amidst FDA Comments and Dr. Prasad’s Departure - timothysykes.com
FinancialContentQURE DEADLINE: Investors of uniQure N.V. (QURE) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on April 13, 2026 - FinancialContent
uniQure (NASDAQ:QURE) Shares Gap Up After Analyst Upgrade - MarketBeat
Wells Fargo Upgrades uniQure (QURE) with Significant Price Targe - GuruFocus
QURE: RBC Capital Upgrades uniQure with a Significant Price Targ - GuruFocus
UniQure (QURE) Shares Surge Following FDA Official's Departure - GuruFocus
uniQure stock jolts higher again after FDA biologics chief set to exit - TechStock²
uniQure (QURE) Receives Upgrades and Sees Pre-Market Boost - GuruFocus
Biotech firm stocks rise on FDA vaccine head’s exit (QURE:NASDAQ) - Seeking Alpha
uniQure (QURE) Stock Surges 36% After FDA Official Vinay Prasad Announces Departure - CoinCentral
uniQure surges following departure of key FDA official - Seeking Alpha
Confusion grows amid uniQure and FDA’s AMT-130 row - The Pharma Letter
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Wells Fargo Upgrades UniQure NV(QURE.US) to Buy Rating, Raises Target Price to $60 - 富途牛牛
RBC Capital Upgrades uniQure to Outperform From Sector Perform, Adjusts Price Target to $35 From $11, Keeps Speculative Risk - marketscreener.com
Why Is uniQure Stock Skyrocketing Monday? - Benzinga
Stock Market Today: Dow Jones, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike—Hims & Hers, Ovintiv, Uniqure In FocusState Street SPDR S&P 500 ETF Trust (ARCA:SPY) - Benzinga
uniQure NV Opens Weak with 12.86% Gap Down Amid Market Concerns - Markets Mojo
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP; April 13, 2026, Lead Plaintiff Deadline - FinancialContent
Shifting Narrative For uniQure (QURE) As FDA Trial Demands Reshape AMT-130 Expectations - Yahoo Finance
uniQure NV Hits Day Low of $15.51 Amid Price Pressure - Markets Mojo
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, A LEADING LAW FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline – Company AnnouncementFT.com - Financial Times
uniQure N.V. $QURE Shares Bought by Vanguard Group Inc. - MarketBeat
Investors of uniQure N.V. (QURE) Seeking RecoveryContact Kaplan Fox Before Deadline on April 13, 2026 - The Chronicle-Journal
Biotech Stock QURE Once Tagged ‘Failed Product’ — CEO Sold Shares Days Before Rally - Stocktwits
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - PR Newswire
Insider Selling: uniQure (NASDAQ:QURE) Insider Sells 3,412 Shares of Stock - MarketBeat
uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 12,000 Shares - MarketBeat
UPCOMING DEADLINE: uniQure N.V. (QURE) Securities Fraud Class Action – April 13, 2026 Lead ... - Bluefield Daily Telegraph
UPCOMING DEADLINE: uniQure N.V. (QURE) Securities Fraud - GlobeNewswire
uniQure N.V. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm ... - Bluefield Daily Telegraph
uniQure N.V. Sued for Securities Law Violations – Investors - GlobeNewswire
FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
Deadline to Lead in Securities Fraud Lawsuit Against uniQure N.V. (QURE) is April 13, 2026Contact Kaplan Fox - FinancialContent
QURE Stock Crashes 32% in a Week: Here's What You Should Know - TradingView
FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial - Sahm
Is US FDA Following Correct Precedent With UniQure Gene Therapy Randomized Trial Demand? - Citeline News & Insights
uniQure (QURE) Faces FDA Demand for Phase 3 Trial for Huntington's Drug - GuruFocus
uniQure used 'distorted comparison' in Huntington's asset trial: FDA official - Seeking Alpha
Kaplan Fox Encourages Investors of uniQure N.V. (QURE) to Contact the Firm Before Lead Plaintiff Deadline on April 13, 2026 - NewMediaWire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - PR Newswire
Holzer & Holzer, LLC Reminds QURE Investors of the April - GlobeNewswire
UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official - marketscreener.com
uniQure's (QURE) Gene Therapy for Huntington's Disease Faces FDA Setback - GuruFocus
uniQure (NASDAQ:QURE) Shares Up 12%Here's Why - MarketBeat
FDA official calls UniQure's Huntington's disease treatment a failure - marketscreener.com
0.28%
17.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):